Gland Pharma Gains FDA Approval for Methylprednisolone Acetate Injectable

Gland Pharma's ANDA approval for Methylprednisolone Acetate Injectable Suspension adds a corticosteroid sterile injectable to its US generics portfolio at a moment when FDA scrutiny of suspension-based injectables remains elevated. The approval covers two strengths, 40 mg/mL and 80 mg/mL, both rated bioequivalent and therapeutically equivalent to Pfizer's Depo-Medrol Injectable Suspension, the reference listed drug.

For QA directors and plant heads working in sterile injectables, corticosteroid suspensions carry a distinct compliance burden. Particle size distribution, resuspendability, and sterility assurance for suspension-based vials demand tighter process controls than standard solution injectables, and bioequivalence demonstration for depot formulations requires pharmacokinetic data that reflects the prolonged-release profile of the RLD. Clearing those requirements under 21 CFR Part 211 and current GMP expectations signals a validated manufacturing baseline at Gland's facility.

The Depo-Medrol market is an established, high-volume segment used across rheumatology, dermatology, and allergy indications. Pfizer's branded product has faced generic competition, and Gland's entry at both strengths positions the company to compete across the full prescribing range. Regulatory affairs leads tracking the injectable generics pipeline will note that dual-strength approvals from a single ANDA submission reflect well-executed formulation development and a coherent comparability strategy against the RLD.

Gland Pharma, majority-owned by Shanghai Fosun Pharmaceutical, has built its US presence predominantly through the sterile injectables segment, and this approval extends that footprint into the corticosteroid suspension category. The company has not disclosed a commercial launch date or supply volume commitments for the US market.

The pace at which Gland converts this approval into commercial supply, and how it positions on price against existing generic entrants, will determine the practical market impact of this ANDA clearance.

Source: Media4Growth via Indian Pharma Post, 2 November 2026.